The Parkinson’s Research Podcast: New Discoveries in Neuroscience
The Michael J. Fox Foundation for Parkinson’s Research presents a podcast that brings listeners to the cutting edge of neuroscience, focusing on Parkinson’s disease. Host Dr. Marie McNeely interviews experts on topics such as genetics, neurodegeneration, neuroimaging, biomarkers, diagnostics, machine learning, drug development, and novel treatment technologies. Aimed at scientists, clinicians, and industry professionals, the show provides in-depth insights into basic science, translational research, and clinical trials for new therapies.
Episodes
31: Podcast Updates with Marie McNeely
In this short episode, host Dr. Marie McNeely shares updates about the podcast and provides listeners with more information on how they can stay connected with MJFF for future podcast episodes as The Parkinson’s Research Podcast merges with The Michael J. Fox Foundation Parkinson’s Podcast. Visit https://www.michaeljfox.org/podcasts for more great podcast episodes, an
30: The Role of Diet and Nutrition in Parkinson’s Disease and Brain Health with Puja Agarwal
It is widely known that a healthy diet can provide essential nutrients and lead to a multitude of benefits, but growing evidence has highlighted important links between diet, nutrition, and brain health, particularly related to neurodegenerative disease. In this episode, Dr. Puja Agarwal discusses her research investigating the role that diet and nutrition may play in Parkinson’s disease and other
29: Developing a Novel App to Improve Speech Intelligibility in Parkinson's Disease with Gemma Moya-Galé
Parkinson's disease significantly impacts various aspects of communication, and this can make it challenging for people with the disease to communicate effectively, be understood by others, and engage in social situations. Dr. Gemma Moya-Galé joins this episode to talk about her work on voice and communication in people with Parkinson’s disease. In particular, she discusses a novel app she an
28: Increasing Diversity in Research and Addressing Brain Health Inequities with Monica Rivera-Mindt
Certain populations are disproportionately affected by neurological diseases, including Parkinson's and other neurodegenerative diseases. A lot of work remains to be done to improve brain health outcomes and promote healthy brain aging across the lifespan, particularly for minoritized, underrepresented populations. Including participants from diverse backgrounds in research helps ensure that the r
27: The Development and Application of the Alpha-Synuclein Seed Amplification Assay with Claudio Soto
Alpha-synuclein plays a key role in the pathophysiology of Parkinson's disease, and researchers have been investigating this protein as a therapeutic target and also as a potential biomarker for the disease. The alpha-synuclein seed amplification assay, developed by Dr. Claudio Soto and colleagues, leverages the self-replicating nature of the misfolded alpha-synuclein proteins that
26: An Inside Look at the Edmond J. Safra Fellowship in Movement Disorders with Marcelo Merello and Sergio Castillo-Torres
To help meet the growing global need for more movement disorders specialists, The Michael J. Fox Foundation created the Edmond J. Safra Fellowship in Movement Disorders in collaboration with longtime partner the Edmond J. Safra Foundation. This program supports the training of movement disorders specialists who will provide expert care and drive advances in Parkinson's research. The program is pos
25: Creating Alpha-Synuclein Cell Lines and Supporting Open Science with Birgitt Schüle
Stem cell models derived from patients with Parkinson’s disease are valuable tools that are helping researchers around the world to better understand the underlying causes of neurodegeneration and to develop biomarkers and new therapies. To maximize the potential impacts of these tools, it is critical that they are developed and shared according to the principles of open science. In her interview,
24: Developing FLEXISyn to Identify and Measure Changes in Alpha-Synuclein in Parkinson's Disease with Judith Steen
New qualitative and quantitative tools are being developed to measure and track changes in proteins relevant for neurodegenerative disease, and these tools have the potential to accelerate drug discovery and clinical trials. In this episode, Dr. Judith Steen discusses her work creating novel qualitative and quantitative tools and workflows at the interface of proteomics and transcriptomics, includ
23: Clinical Applications of Biomarkers and Large-Scale Collaborative Research with Charles Adler
Substantial research has focused on identifying biomarkers for the diagnosis of Parkinson's disease (PD) as well as monitoring progression of the disease. In developing these biomarkers, it is critical for scientists to consider how the biomarkers will ultimately be used in the clinic and in clinical trials research. In this interview, Dr. Charles (Chuck) Adler shares his perspectives on how bioma
22: Investigating Light Therapy For Sleep and Motor Function in People with PD with Beatrix Feigl
Sleep disturbances, such as insomnia, sleep fragmentation, excessive daytime sleepiness, and REM sleep behavior disorder are common in people with Parkinson's disease (PD). Poor sleep quality can also impact other domains of function, including motor function. Prior research has shown that a type of photoreceptor cell in the retina, called melanopsin cells, provide the main light signals to the br
21: The Autophagy-Lysosomal Pathway and Development of Relevant PD Biomarkers with Zhenyu Yue
Though existing evidence supports that dysfunction in the clearing of cellular debris plays an important role in the development of Parkinson's disease, many unanswered questions remain regarding the mechanisms of the autophagy-lysosomal pathway involved in this process. In particular, research in the field has been limited by a lack of reliable, quantitative tests for monitoring autopha
20: Studying CSF Element Profiles and Tear Fluid as Potential Biomarkers, and Novel and Combined Therapies for PD with Paul Lingor
Evidence supports that dysfunction in the homeostasis of iron and other elements likely contributes to the pathophysiological mechanisms of Parkinson's disease, but we have yet to develop suitable elemental biomarkers for use in diagnosing and monitoring the progression of Parkinson's disease. Dr. Paul Lingor discusses his work in this area to identify patterns of bioelements in CSF that coul
19: Current and Emerging Imaging Biomarkers for Diagnosis and Prognosis of PD and Atypical Parkinsonism with Antonio Strafella
Identifying reliable biomarkers for the diagnosis and prognosis of Parkinson's disease and atypical parkinsonism would have substantial impacts on clinical trials and clinical practice. A particularly active area of research is the development of novel molecular imaging biomarkers that can be used in combination with common neuroimaging approaches. Dr. Antonio Strafella discusses cu
18: Examining Links Between Environmental Exposure, Poor Olfaction, and Parkinson's Disease with Honglei Chen
Prior studies have established links between poor olfaction and Parkinson's disease, and impaired sense of smell is a common prodromal symptom of Parkinson's disease. The causes and mechanisms of prodromal neurodegeneration are actively being researched. However, environmental exposure to pesticides or other chemicals may trigger or modify the course of neurodegeneration, potentially leading to th
17: Developing Interventions to Improve Gait and Increase Physical Activity in Parkinson’s Disease with Gammon Earhart
Gait impairments such as slow speed, small steps, and high variability from step to step are common in people with Parkinson's disease, and these changes begin to occur early in the course of disease. Freezing of gait may develop later for some individuals, and it has been linked to falls and other adverse outcomes. When the quality of walking declines, it can lead to a reduction in the quant
16: Studying Basal Ganglia Circuits and Developing Deep Brain Stimulation Protocols for Longer-Lasting Effects with Aryn Gittis
Improving our understanding of the complex neural circuits involved in normal function of the basal ganglia and other parts of the brain impacted by Parkinson's disease is critical for developing more targeted and more effective treatment approaches. In this episode, Dr. Aryn Gittis discusses her research examining how the activity of specific basal ganglia circuits relates to motor cont
15: Innovative Fellowship Program is Training Tomorrow's Parkinson's Leaders with Rachel Dolhun
Demand for movement disorder specialists continues to grow, but not enough neurologists are receiving focused training in Parkinson’s and related conditions in order to meet the current and projected needs in the U.S. and around the world. In collaboration with longtime partner the Edmond J. Safra Foundation, The Michael J. Fox Foundation created the Edmond J. Safra Fellowship in Movement Disorder
14: Evidence Linking Parkinson's Disease Risk and Environmental Exposure to Trichloroethylene (TCE) with Sam Goldman
Trichloroethylene (TCE) and related chemicals like perchloroethylene (PCE) have been used widely for a variety of commercial purposes over the past century, and these chemicals are prevalent in the air, water, and soil. Over the past several decades, mounting evidence has been published linking exposure to TCE/PCE with adverse health effects, including cancer and Parkinson's disease. In this
13: New Advances in Neurosurgical Interventions for Parkinson's Disease with Doris Wang
For over a century, different surgical interventions have been explored to address symptoms of Parkinson's disease, and researchers are continuing to innovate and improve surgical treatments today. With new technology and an ever-expanding understanding of the function of the nervous system and the pathophysiology of Parkinson's disease, neurosurgical interventions are becoming more effective and
12: Accelerating Discovery by Developing and Distributing Research Tools with Nicole Polinski
The Michael J. Fox Foundation for Parkinson's Research established its Research Tools Program to address gaps in the field and common challenges surrounding the development of reagents and models that slowed the initial stages of promising research projects. In collaboration with many partners and stakeholders, the Research Tools Program helps ensure that scientists around the world have acce
11: The Importance of Sex and Gender Factors in Neurodegenerative Disease Research and Care with Antonella Santuccione Chadha
Increasing evidence supports the presence of sex and gender differences in neurodegenerative conditions, including Alzheimer's disease and Parkinson's disease. There is a critical need to more closely examine sex and gender differences in all stages of research, therapeutic development, and clinical treatment to enable better outcomes through precision medicine approaches. This episode focuses on
10: Understanding Genetics, Pathology, and Progression in Parkinson's Disease and Atypical Parkinsonian Syndromes with Huw Morris
Atypical Parkinsonian Syndromes, such as progressive supranuclear palsy (PSP), multiple system atrophy (MSA), corticobasal degeneration (CBD), and dementia with Lewy bodies are often initially diagnosed as Parkinson's disease. Incorrect, incomplete, or delayed diagnoses are barriers to beginning the most appropriate treatment early in the disease course. More research is needed to facilitate
9: Examining the Proposed Biological Definition of Neuronal Alpha-Synuclein Disease and Staging System with Lana Chahine
For many years, Parkinson's disease and dementia with Lewy bodies have been defined using clinical features. With recent advances in biomarkers, particularly the alpha-synuclein seed amplification assay that allows us to detect misfolded and aggregated alpha-synuclein in cerebrospinal fluid, it is now possible to identify the presence of pathological neuronal alpha-synuclein in living pa
8: Managing Risk for Drug Discovery and Development in Parkinson's Disease with Kalpana Merchant
There is a pressing need to develop safe and effective disease-modifying and symptomatic treatments for Parkinson's disease. Through improvements in our understanding of the pathophysiology of the disease, as well as genetic risk factors, new potential treatment targets have emerged. However, bringing a promising new compound from the lab through all of the steps of drug development is a long
7: Using Neuroimaging and Biomarkers to Improve Neurodegenerative Disease Diagnosis and Assessment with John Seibyl
In neurodegenerative conditions such as Parkinson's disease (PD), patients often do not receive a diagnosis until the hallmark motor symptoms begin to manifest. This can be a decade or more after substantial changes start occurring in the brain. A major goal of the PD research field has been to develop methods for earlier detection and intervention. Over the years, there have been substa
6: Impacts and Goals of the Global Parkinson's Genetics Program with Christine Klein
A substantial portion of people with Parkinson's disease (PD) have a family history of the disease, and new findings continue to improve our understanding of relevant genetic variants. These discoveries are key for clarifying the mechanisms that lead to Parkinson's disease as well as the development of new therapies. The Global Parkinson's Genetics Program (GP2) was established to gather and integ
5: The Role of Inflammation and Immune Responses in Neurodegeneration with Malú Gámez Tansey
A growing body of evidence is expanding our understanding of the links between inflammation, our immune responses, brain health, and neurodegeneration. In particular, several genes associated with Parkinson's (including LRRK2) are known to be involved in inflammation, and peripheral inflammation has been shown to influence brain function and contribute to the development of neurodegenerative
4: Elucidating the Pathobiology of LRRK2 in Parkinson's Disease with Dario Alessi
Mutations in the LRRK2 gene were first linked to Parkinson's disease (PD) risk in 2004. Since then, researchers from around the world have advanced our understanding of the mechanisms through which LRRK2 may contribute to PD, leading to the development of three potential LRRK2-targeted therapies that are now being evaluated in clinical trials. Along with colleagues and collaborators, Dr. Dario Ale
3: New Frontiers in Deep Brain Stimulation Research for Parkinson’s disease with Michael Okun
For decades, researchers, clinicians, and industry professionals have continued to study and optimize deep brain stimulation (DBS) with the goal of providing the best possible personalized treatment for Parkinson’s disease (PD) and other neurological conditions. In this episode, Dr. Michael Okun joins us to discuss his research and some of the recent advances in deep brain stimulation and other ar
2: Understanding Sleep Differences in Parkinson’s Disease with Dr. Amy Amara
Sleep impacts our lives in many different ways, and Dr. Amy Amara joins us in this episode to discuss her career and findings from her research on sleep in Parkinson’s disease (PD). She shares her insights on the characteristics of sleep in people with Parkinson’s disease, how sleep can be impacted by exercise, medications, and deep brain stimulation, and how studying rapid eye movement (REM) slee
1: Industry Contributions and Collaborations in Parkinson's Research with Karoly Nikolich
In this episode, serial entrepreneur Dr. Karoly Nikolich shares his perspectives on the industry side of the state of neuroscience, as well as areas of opportunity and the role of industry in advancing the field. He also discusses recent major breakthroughs, the importance of industry partnerships, including collaborations with The Michael J. Fox Foundation (MJFF), and how he is working to advance
0: The Parkinson's Research Landscape and the Role of MJFF with Brian Fiske and Mark Frasier
New research advances are expanding our knowledge of Parkinson's disease and bringing us closer to the ultimate goals of new treatments, effective cures, and disease prevention. In this introductory episode, you'll hear from Dr. Brian Fiske and Dr. Mark Frasier, Co-Chief Scientific Officers at The Michael J. Fox Foundation for Parkinson's Research (MJFF). During the conversation, they provide thei
Recommended
15 Minutes of Infamy
15 Minutes with Jesus: Christian Meditation, Guided Prayer, Bible Study, Emotional Healing, Devotional, Hear God’s Voice
180Podcast.
1856 Podcast-YMCA of South Hampton Roads
1984
1984, by George Orwell
19 Keys Presents High Level Conversations
19 Observations on mining and refining of critical minerals
1A
1Dime Radio
오늘 미국은
$100M Offers by Alex Hormozi, Book Summary, Podcast, English
